A potential cure for a rare type of blood cancer is currently being used to treat 150 patients at various healthcare centers ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early ...

New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex Faspro in patients with high-risk smoldering multiple myeloma.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...

A case analysis provides a new understanding of the ocular side effects of Blenrep, an antibody drug conjugate that is being ...